Hussman Strategic Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Hussman Strategic Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,150	Closed	-$1.47M	–	309
2024 Q3	$1.47M	Hold	3,150	–	–	0.36%	119
2024 Q2	$1.48M	Hold	3,150	–	–	0.41%	107
2024 Q1	$1.32M	Hold	3,150	–	–	0.31%	123
2023 Q4	$1.28M	Sell	3,150 -4,650	-60%	-$1.72M	0.29%	135
2023 Q3	$2.71M	Hold	7,800	–	–	0.52%	65
2023 Q2	$2.74M	Sell	7,800 -4,600	-37%	-$1.55M	0.51%	54
2023 Q1	$3.91M	Hold	12,400	–	–	0.61%	32
2022 Q4	$3.58M	Hold	12,400	–	–	0.58%	51
2022 Q3	$3.59M	Hold	12,400	–	–	0.62%	40
2022 Q2	$3.49M	Buy	12,400 +9,800	+377%	+$2.62M	0.6%	39
2022 Q1	$679K	Hold	2,600	–	–	0.13%	223
2021 Q4	$571K	Sell	2,600 -6,700	-72%	-$1.3M	0.13%	231
2021 Q3	$1.69M	Hold	9,300	–	–	0.37%	111
2021 Q2	$1.88M	Buy	9,300 +2,100	+29%	+$439K	0.39%	99
2021 Q1	$1.55M	Buy	7,200 +2,100	+41%	+$461K	0.32%	116
2020 Q4	$1.21M	Buy	+5,100	New	+$1.17M	0.32%	126

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Hussman Strategic Advisors's VRTX Position: Q4 2024 in Review

Hussman Strategic Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 3,150 shares — an estimated $1.47M sold.

Hussman Strategic Advisors first reported a position in VRTX in Q4 2020 and held it in 16 quarters. The position peaked at $3.91M in Q1 2023. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Hussman Strategic Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Hussman Strategic Advisors sold 3,150 Vertex Pharmaceuticals shares in Q4 2024, an estimated $1.47M.
Hussman Strategic Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 16 quarters.
Hussman Strategic Advisors's Vertex Pharmaceuticals position peaked at $3.91M in Q1 2023.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Hussman Strategic Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.